The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
The Journal of Infectious Diseases2009Vol. 199(7), pp. 936–944
Citations Over TimeTop 1% of 2009 papers
Cosette M. Wheeler, Susanne K. Kjær, Kristján Sigurðsson, Ole‐Erik Iversen, Mauricio Hernández-Ávila, Gonzalo Pérez, Darron R. Brown, Laura A. Koutsky, Eng Hseon Tay, Patricia García, Kevin A. Ault, Suzanne M. Garland, Sepp Leodolter, Sven‐Eric Olsson, Grace Tang, Daron G. Ferris, Jorma Paavonen, Marc Steben, F. Xavier Bosch, Joakim Dillner, Elmar A. Joura, Robert J. Kurman, Sławomir Majewski, Nubia Muñóz, Evan R. Myers, Luisa L. Villa, Frank J. Taddeo, Christine C. Roberts, Amha Tadesse, Janine T. Bryan, Lisa Lupinacci, Katherine Giacoletti, Margaret K. James, Scott Vuocolo, Teresa M. Hesley, Eliav Barr
Abstract
ClinicalTrials.gov identifiers: NCT00092521 , NCT00092534 , and NCT00092482.
Related Papers
- The expression and clinical significance of p16 protein in cervical cancer and cervical intraepithelial neoplasia(2010)
- Expressions of P16~(INK4A) and Ki-67 and HPV infection in cervical intraepithelial neoplasia and cervical cancer(2011)
- Expressions of 14-3-3σ in cervical cancer and cervical intraepithelial neoplasia(2009)
- [Study on Dynamic Changes of Human Papillomavirus 16 E5 Gene in the Occurrence of Cervical Cancer].(2019)
- → Expression of eIF-4A protein in cervical carcinoma and its clinical significance(2015)